SCHEMBL30706745

SCHEMBL30706745

F/C=C1/CN2CCCC2(COc2ncc3cncc(F)c3n2)C1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 19/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30699447 0.88 KRAS (0.34) KRAS
SCHEMBL30391380 0.85 KRAS (0.42) KRAS
SCHEMBL29679980 0.78 KRAS (0.47) KRAS
Trifluoroacetic Acid SCHEMBL30391092 0.77 KRAS (0.38) KRAS
SCHEMBL30390890 0.77 KRAS (0.44) KRAS
Trifluoroacetic Acid SCHEMBL30391309 0.77 KRAS (0.38) KRAS
Hydrochloric Acid SCHEMBL30390538 0.76 KRAS (0.44) KRAS
SCHEMBL24272822 0.69 — —
SCHEMBL26283048 0.69 — —
SCHEMBL27269373 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540255-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
Send feedback